116 results
Page 5 of 6
8-K
EX-99.2
yw2ni rwur881ht
10 Oct 19
Entry into a Material Definitive Agreement
9:39pm
8-K
EX-2.1
s1plwlux5v87s5u2 s1
10 Oct 19
Entry into a Material Definitive Agreement
9:39pm
8-K
EX-99.1
6jday ilwth8ikhmd
8 Aug 19
Undertaking strategic review of commercial and R&D assets
4:15pm
8-K
EX-99.1
kqv10
5 Jun 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
it5282v
8 May 19
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
4:15pm
8-K
EX-99.1
sc3muzklz
4 Apr 19
Regulation FD Disclosure
7:06am
8-K
EX-99.1
ch6b6p0xv c08abten8
18 Mar 19
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
7:15am
8-K/A
EX-99.2
31zflpc
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K/A
EX-99.3
o15q0j pxum
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K/A
EX-23.2
7f539vv
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K
EX-99.1
th9rw06x28qvn6f
6 Nov 18
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
4:15pm
424B5
i5kf t232q
18 Oct 18
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.3
f48szhgu4qiv0r6sr
18 Oct 18
Aclaris Announces Proposed Public Offering of Common Stock
4:01pm
424B5
ndujy
17 Oct 18
Prospectus supplement for primary offering
4:04pm